Company: IMRX
Filing Date: 2025-03-20
Form Type: 424B5
Source: 0001104659-25-026222
Chunk: 0

Company: Immuneering Corp
Filing Date: 2025-03-20
Form: 424B5
Chunk 0
---
As Filed Pursuant to Rule 424(b)(5)

Registration No. 333-266738

PROSPECTUS SUPPLEMENT

(To Prospectus and Prospectus Supplement dated August 19, 2022)

<div align='center'>IMMUNEERING CORPORATION

Up to $21,503,435.70 of Class A Common Stock</div>

This prospectus supplement
(the “Prospectus Supplement”) supplements the prospectus dated August 19, 2022 and the prospectus supplement dated August 19,
2022 (together, the “ATM Prospectus”), relating to the offer and sale of shares of our Class A common stock from time
to time pursuant to the terms of the Equity Distribution Agreement, dated August 10, 2022 (the “Agreement”), with Piper
Sandler & Co. (“Piper”) as sales agent. During the twelve calendar months prior to, and including, the date hereof,
we have sold an aggregate of 6,155,556 shares of our Class A common stock for aggregate gross proceeds of $18.7 million through Piper
under the Agreement. This Prospectus Supplement should be read in conjunction with the ATM Prospectus, and is qualified by reference thereto,
except to the extent that the information herein amends or supersedes the information contained in the ATM Prospectus. This Prospectus
Supplement is not complete without, and may only be delivered or utilized in connection with, the ATM Prospectus, and any future amendments
or supplements thereto.

On March 20, 2025, upon
filing our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, we became subject to the offering limits
in General Instruction I.B.6 of Form S-3. As of the date of this Prospectus Supplement, the aggregate market value of our Class A
common stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 is $$64,510,307.10, which was calculated based
on 30,004,794 shares of our outstanding Class A common stock held by non-affiliates and a price of $2.15 per share, the closing price
of our Class A common stock on January 23, 2025, which is the highest closing sale price of our Class A common stock on
the Nasdaq Global Market within the prior 60 days. As of the date of this Prospectus Supplement